Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 4Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, B-Cell 1Lymphatic Metastasis 1Leukemia 1Head and Neck Neoplasms 1Cardiotoxicity 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Atherosclerosis 1Aggression 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Rituximab 5Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Cytarabine 4Busulfan 4Azacitidine 4AP 1903 reagent 4venetoclax 3ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Etoposide 3pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × Positron Emission Tomography Computed Tomography × Clear all
NCT01920737 2025-09-16

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
39 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡